CAMBRIDGE, Mass., February 07, 2025--eGenesis announces second patient successfully transplanted with genetically engineered ...

Maze Therapeutics, Inc. (NASDAQ: MAZE), a clinical-stage biopharmaceutical company with a market capitalization of $569 million, has dosed the first patient in its Phase 2 HORIZON Study of MZE829, ...

Though highly effective, medications for the prevention of chronic kidney disease progression are under-utilized, emphasizing the need for better use of prognostic tools.

Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with ...

A New Hampshire man fought for the chance at a pig kidney transplant, spending months getting into good enough shape to be ...

For the second time in less than a year, doctors at Massachusetts General Hospital have transplanted a genetically-edited pig ...

Millions of people worldwide take proton pump inhibitors (PPIs) to relieve heartburn, acid reflux, and gastroesophageal ...

In the latest study, researchers found the main genetic mutations in renal cell cancer, possibly by using artificial intelligence (AI). The scientists injected mRNA vaccine made against proteins ...

A personalized neoantigen cancer vaccine generated strong immune responses in renal cell carcinoma patients, leading to ...

The FDA will allow two biotechnology companies to run clinical trials: United Therapeutics and eGenesis. United Therapeutics ...

A small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successful, ...